Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one.

Gregory M PetersonJackson ThomasKwang C YeeSam KosariMark NauntonInger H Olesen

Published in: Journal of clinical pharmacy and therapeutics (2018)

Thorough research, the development of panels of biomarkers and individualization of therapy will be necessary to optimize the use of these combinations and minimize the substantial risk of overstimulating the immune system.

Keyphrases

monoclonal antibody
papillary thyroid
stem cells
squamous cell
cell therapy
bone marrow
lymph node metastasis